Technology & Innovation

Innovation Advantages: Uniqueness & Primacy

Specialized Diagnostics

Innovative Diagnostics, Delivering Value

Innovative Pharmaceuticals

Novel Targets, Novel Mechanisms, and First-in-Class (FIC) Drug Development

Health Management

Research & Academic Achievements

09/ 2026

Impact Factor 27.7! Published in Molecular Cancer

This study is the first to reveal how GP73 promotes colorectal cancer liver metastasis by regulating exosome biogenesis. GP73 binds to cholesterol and remodels the exosomal proteome of hepatocytes, resulting in the generation of NAV2-enriched exosomes

Read more +

09/ 2024

GlyExo-Capture®: An Innovative High-Throughput and Rapid Enrichment and Isolation Technology for Glycosylated Cell-Derived Extracellular Vesicles (glyCOEVs)

This study proposes an innovative GlyExo-Capture® technology for the high-throughput and rapid enrichment and isolation of glycosylated cell-derived extracellular vesicles (glyCOEVs)...

Read more +

02/ 2024

A Novel Mechanism of GP73 in Liver Injury Assessment Published in Nature Communications

This study identifies the hepatocyte-specific lectin asialoglycoprotein receptor 1 (ASGR1) as a potential genetic determinant of susceptibility to liver injury and proposes its potential application as a...

Read more +

01/ 2022

Published in Nature Metabolism

This study reveals that aberrant secretion of the Golgi membrane protein GP73 caused by SARS-CoV-2 infection is a major contributor to the abnormal elevation of blood glucose levels induced by SARS-CoV-2 infection...

Read more +

01/ 2021

Study on a Novel Pathogenic Mechanism of Non-Obese NAFLD Published in Nature Communications

The study revealed the pathophysiological role of GP73 in the development and progression of non-obese NAFLD, expanding the understanding of its pathogenesis and providing potential opportunities for clinical intervention.

Read more +

12/ 2020

Study on the Mechanism of SARS-CoV-2 Infection Published in Nature Metabolism

This study reveals that scavenger receptor class B type 1 (SR-B1) serves as a co-receptor for SARS-CoV-2, highlighting its potential as a novel target for anti-SARS-CoV-2 drug development and providing new insights into the development of therapeutics for SARS-CoV-2 infection...

Read more +

Technology & Innovation

First IVD Company Listed on the STAR Market of the Shanghai Stock Exchange (688068.SH)

UP-Converting Phosphor Technology Platform Received the Second Prize of the National Technology Invention Award in 2015

Chinese Liver Health Project (CLHP) Featuring More Than 10 Specialized Diagnostic Products

First to Successfully Develop COVID-19 Immunoassay Reagents

GlyExo-Capture^®：World’s First Automated Testing Platform for Exosome Isolation and Enrichment for Early Cancer Screening

First NMPA-Approved Product for Hair-Based Drugs-of-Abuse Testing

First-in-Class! Sungen Biomed’s SGC001 Antibody Therapeutic for Acute Myocardial Infarction

First-in-Class! Youngen Biotech’s Kardia Shuttle^® Cardiac-Targeting Platform for Small Nucleic Acid Therapeutics

AI R&D Platform

X-Gen AI Drug Discovery & Design Research Center

Digital Biomarker

Target Discovery

Nucleic Acid Drug
Design

Protein Drug
Design

siRNA Drug Design Platform

Target Discovery Platform

Protein Drug Design Platform

Design &Optimization

De-novo design

Sequence design

Affinity maturation

Evaluation &Screening

Molecular docking

Molecular dynamics (MD) simulation

Affinity evaluation

Druggability assessment.

Dry-Wet Closed Loop

Experimental data feedback loop

Model fine-tuning and iteration

Self-learning strategies

Digital Biomarkers

Large Model for Liver Health Management in High-Risk Populations

Leveraging digital-intelligent diagnostic solutions to enable proactive management of liver-disease populations.

C-GALAD Model

Integrating five core features: age, sex, alpha-fetoprotein (AFP), AFP-L3 ratio (AFP-L3%), and des-gamma-carboxy prothrombin (DCP), it has been deployed in nearly 100 hospitals nationwide, with its clinical value continuously being validated.

Digital Biomarkers of Aging

Breaking through the technical bottleneck where traditional biomarkers cannot independently reflect aging status, we establish precise and quantifiable digital biomarkers of aging to enable early detection of immunosenescence and assessment of aging-intervention efficacy.